ArticleMedicine2025
Cardiac metastasis in endometrial carcinoma: A rare case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleEndometrial carcinoma (EC) is a frequently occurring cancer in the female reproductive system. Nevertheless, the occurrence of cardiac metastasis in cases of EC is uncommon and represents a significant risk to women's health. PATIENT CONCERNS: A 58-year-old female patient experienced abnormal vaginal bleeding for over 8 months and was eventually diagnosed with stage IVC (FIGO 2023) endometrial cancer characterized by mismatch repair deficiency that had spread to the heart. DIAGNOSES: Stage IVC (FIGO 2023) mismatch repair deficiency EC with cardiac metastasis.
interventionsAfter a thorough discussion with the multidisciplinary team, a detailed noninvasive treatment strategy was established: the initial phase involved 6 cycles of induction therapy using a combination of paclitaxel and carboplatin along with tislelizumab, resulting in a partial response. This was followed by 3 cycles of maintenance therapy with tislelizumab as a standalone treatment. OUTCOMES: Following the maintenance treatment, the cardiac metastasis was entirely eliminated. The patient experienced a progression-free survival duration of 9 months. LESSONS: For patients with EC who have metastasized to rare sites such as the heart, comprehensive management guided by multidisciplinary team consultation is crucial, as it can significantly prolong survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.